A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2015
Price : $35 *
At a glance
- Drugs N 6022 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms SNO-1
- Sponsors N30 Pharma; Nivalis Therapeutics
- 23 Nov 2014 Planned End Date changed from 1 Nov 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 23 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 23 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.